Osteoarthritis year in review 2024: Epidemiology and therapy
Остеоартрит: обзор за 2024 год. Эпидемиология и терапия
2024-08-03
SCID: 54.1/a7fn2b36
Discuss with AI
Global Burden of Diseaseosteoarthritis epidemiologyosteoarthritis risk factorsosteoarthritis therapyrandomized controlled trials
Figures from the paper
Abstract (AI)
This "Year in Review" presents a curated selection of research themes and individual studies within the clinical osteoarthritis (OA) field, focusing on epidemiology and therapy. The search was conducted in electronic database MEDLINE from March 4, 2023, to March 31, 2024, specifically targeting English-language articles involving human participants. Inclusions were based on perceived importance and relevance to identifying risk factors or advancing OA treatments. A total of 6539 studies were screened by the 5 authors, resulting in 157 studies considered for potential inclusion. Ultimately, 44 studies were selected, uncovering six key OA-related themes: i) the burden of OA (mostly from Global Burden of Disease studies), ii) pain drivers and trajectories, iii) impacts of sex/gender, iv) OA risk factors, and treatments for v) hand and vi) knee OA. The prevalence of OA continues to rise, particularly affecting women, with unclear distinctions in risk factors and treatment responses between sexes. Associations with atopy were demonstrated in two significant databases. Notably, the authors were particularly interested in recent high-quality methodology randomized controlled trials focusing on hand (methotrexate, denosumab, colchicine, topical betamethasone) and knee OA with conflicting results about stem cell injection. These findings collectively contribute to show the growing burden of OA, but also to help the understanding of OA pathophysiology and inform ongoing efforts to enhance management for people with OA.
Key Findings
1
Evidence remains unclear regarding sex-specific osteoarthritis risk factors and differences in treatment responses.
2
Recent randomized controlled trials evaluated methotrexate, denosumab, colchicine, and topical betamethasone for hand osteoarthritis, while knee osteoarthritis stem-cell injection studies produced conflicting results.
3
The prevalence and overall burden of osteoarthritis continue to rise, with women particularly affected.
4
The review screened 6,539 studies and selected 44 studies addressing osteoarthritis epidemiology, pain, sex and gender, risk factors, and hand and knee treatments.
5
Two major databases demonstrated associations between atopy and osteoarthritis.
Research Object
clinical osteoarthritis (OA) in humans, particularly hand and knee OA
Research Subject
epidemiology, risk factors, pain trajectories, sex/gender differences, and treatment effectiveness in osteoarthritis
Publication Details
Publication Date
2024-08-03
Journal
Publisher
ISSN
Cited by
469
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest